Percentage of Participants With Immediate Adverse Events (AEs) According to Severity, and Investigator-assessed Causality;Percentage of Participants With Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, AEs of Special Interest (AESIs), and Deaths;Percentage of Participants With Solicited AEs According to Severity;Percentage of Participants With Unsolicited AEs According to Severity, and Investigator-assessed Causality;SARS-CoV-2 Neutralizing Antibody (Nab) Responses;SARS-CoV-2 Neutralizing Antibody (Nab) Responses: GMFR;SARS-CoV-2 Neutralizing Antibody (Nab) Responses: GMT;SARS-CoV-2-specific T Helper 1 (Th1) Cell-mediated Immune (CMI) Responses;SARS-CoV-2-specific T Helper 2 (Th2) CMI Responses

Percentage of Participants With Immediate Adverse Events (AEs) According to Severity, and Investigator-assessed Causality;Percentage of Participants With Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, AEs of Special Interest (AESIs), and Deaths;Percentage of Participants With Solicited AEs According to Severity;Percentage of Participants With Unsolicited AEs According to Severity, and Investigator-assessed Causality;SARS-CoV-2 Neutralizing Antibody (Nab) Responses;SARS-CoV-2 Neutralizing Antibody (Nab) Responses: GMFR;SARS-CoV-2 Neutralizing Antibody (Nab) Responses: GMT;SARS-CoV-2-specific T Helper 1 (Th1) Cell-mediated Immune (CMI) Responses;SARS-CoV-2-specific T Helper 2 (Th2) CMI Responses

SARS-CoV-2 neutralizing antibody (Nab) responses;SARS-CoV-2-specific T helper 1 (Th1) cell-mediated immune (CMI) responses;SARS-CoV-2-specific T helper 2 (Th2) CMI responses;The incidences and severity of the following solicited AEs;The incidences of serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal, AEs of special interest (AESIs), and deaths;The incidences, severity, and investigator-assessed causality of immediate adverse events (AEs);The incidences, severity, and investigator-assessed causality of unsolicited AEs

SARS-CoV-2 neutralizing antibody (Nab) responses;SARS-CoV-2-specific T helper 1 (Th1) cell-mediated immune (CMI) responses;SARS-CoV-2-specific T helper 2 (Th2) CMI responses;The incidences and severity of the following solicited AEs;The incidences of serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal, AEs of special interest (AESIs), and deaths;The incidences, severity, and investigator-assessed causality of immediate adverse events (AEs);The incidences, severity, and investigator-assessed causality of unsolicited AEs